| Drug Name |
Secukinumab |
| Drug ID |
BADD_D02001 |
| Description |
Secukinumab (Cosentyx) is a human monoclonal antibody designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin-17A (IL-17A) inhibitor marketed by Novartis. IL-17 is a group of proinflammatory cytokines released by cells of the immune system and and exist in higher levels in many immune conditions associated with chronic inflammation. By targeting IL-17A, secukinumab has shown excellent efficacy in psoriasis by normalizing skin histology and was approved by the United States Food and Drug Administration on January 21, 2015 to treat adults with moderate-to-severe plaque psoriasis. |
| Indications and Usage |
For the treatment of moderate to severe plaque psoriasis in patients that are candidates for systemic therapy or phototherapy. |
| Marketing Status |
approved |
| ATC Code |
L04AC10 |
| DrugBank ID |
DB09029
|
| KEGG ID |
D09967
|
| MeSH ID |
C555450
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
0078-1070; 0078-1056; 0078-0639 |
| UNII |
DLG4EML025
|
| Synonyms |
secukinumab | Cosentyx | AIN 457 | AIN457 | AIN-457 |
